Swiss biotech Idorsia (SIX: IDIA) has announced positive top-line results from the first Phase III study of its dual orexin receptor antagonist, daridorexant.
Shares in the company leapt over a tenth following the news that the trial, which is testing the candidate as a treatment for insomnia, met efficacy goals of objective and subjective sleep parameters.
The trial also met goals on daytime performance with no residual effect in the morning, with no evidence of rebound or withdrawal symptoms upon treatment discontinuation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze